In my doctoral research I made the surprising discovery that genetic changes induced by an important class of environmental carcinogens, the aromatic amines, failed to correlate with liver tumor formation (Wang et al. Env Mol Mutagen 2012). Subsequently I identified a novel oxidization pathway for the model aromatic amine 4-aminobiphenyl (Wang et al. Drug Metab Dispos 2015), that leads to redox imbalances and may contribute to liver tumor burden (Wang et al. Toxicol Sci 2015, Wang et al. Pharmacol Ther 2019). I was also involved in a successful collaboration that led to improved differentiation of ESC and iPSC into hepatocytes (Ogawa…Wang et al. Development 2013). Together these discoveries shaped my research interest in “epi-genetic” factors that control liver development and regeneration.In my postdoctoral training I began to explore how the epigenome regulate liver biology, leading to the discovery of a novel layer of epigenetic crosstalk that improves the regeneration capacity of the mammalian liver (Wang et al. Curr Top Dev Biol 2016, Chernyavskaya…Wang et al. Development 2017, Wang et al. Dev Cell 2019). I am currently investigating how epigenomic reprogramming affects hepatic stellate cell biology in the laboratory of Dr. Scott Friedman who first established these cells as the driver of liver fibrosis.
BSc, University of Toronto
PhD, University of Toronto
PostDoc, Icahn School of Medicine at Mount Sinai
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Wang did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.